BlossomHill Therapeutics, Inc. - 10-Q Filing

BlossomHill Therapeutics reports Q3 2026 results with focus on R&D for BH-30643, BH-30236, and BH-501284 candidates.

SEC EDGAR ·

Tickers: $BLSM

Read the full article at SEC EDGAR

More Regulatory news